Recent Transactions

04-Oct-16
$223 million
U.S.A., U.K. flags
Target: 

U.S. rights to Toprol-XL (AstraZeneca)

Canada flag
Acquiror: 
Aralez Pharmaceuticals Inc.

Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the U.S. rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.

09-Aug-16
$NA
Australia flag
Target: 

Bionomics Limited

flag not available

Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.

16-Dec-11
$NA
United States flag
Target: 

ISTA Pharmaceuticals, Inc.

Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives

09-May-11
$843 million
Canada flag
Target: 

The Forzani Group Ltd.

Canada flag
Acquiror: 
Canadian Tire Corporation, Limited

Advised The Forzani Group Ltd., Canada's largest national retailer of brand-name and private-brand sporting goods, apparel and footwear, on its sale to Canadian Tire Corporation, Limited

07-Feb-11
$548 million
United States flag
Target: 

Wesco Financial Corporation

United States flag
Acquiror: 
Berkshire Hathaway Inc.

Advised the Special Committee of Wesco Financial Corporation in connection with Berkshire Hathaway Inc.'s proposal to acquire the remaining 19.9% of the shares of Wesco’s common stock that it does not presently own

15-Dec-10
$12.9 billion
U.S.A., Swiss flags
Target: 

Alcon, Inc.

Switzerland flag
Acquiror: 
Novartis AG

Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company

23-Apr-08
$2.8 billion
United States flag
Target: 

Wendy's International, Inc.

United States flag
Acquiror: 
Triarc Companies, Inc.

Advised the special committee of the board of directors in connection with its merger with Triarc Companies, Inc., the operator of the Arby’s franchise. The combined systems will have approximately 10,000 restaurant units and pro forma annual system sales of approximately $12.5 billion, positioning it as the nation’s third largest quick service restaurant company

30-Mar-07
$24.4 billion
United Kingdom flag
Target: 

Alliance Boots plc

United States flag
Acquiror: 
Kohlberg Kravis Roberts & Co. Ltd. and Stefano Pessina

Advised Alliance Boots plc, the leading international pharmacy-led health and beauty group, on a proposal regarding an offer for the company from a consortium comprising of Kohlberg Kravis Roberts & Co. Ltd. and Stefano Pessina

09-Sep-05
$1.0 billion
United States flag
Target: 

7-Eleven, Inc.

Japan flag
Acquiror: 
Seven-Eleven Japan Co., Ltd

Advised the special committee of 7-Eleven, Inc. in connection with its evaluation of an unsolicited tender offer commenced by Seven-Eleven Japan Co., Ltd

show all